LNAI

Lunai Bioworks Inc

Apr 08 • 04:00PM ET

0.3570

-0.0371 -9.41 %

Healthcare • Biotechnology • USA • NASD

Apr 07, 9:10 AMLunai Bioworks wins first revenue-generating multi-year defense collaboration via BioSymetrics AI platform for chemical threat assessment

Peers: ENPH SEDG RUN CSIQ FSLR JKS NOVA AY NEE

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-7.55	Insider Own	45.24%	Shs Outstand	24.19M	Perf Week	-12.39%
Market Cap	8.63M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	13.25M	Perf Month	62.27%
Enterprise Value	10.89M	PEG	-	EPS next Q	-	Inst Own	4.60%	Short Float	22.91%	Perf Quarter	-61.19%
Income	-125.52M	P/S	-	EPS this Y	-	Inst Trans	-1.43%	Short Ratio	0.16	Perf Half Y	-71.89%
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-212.74%	Short Interest	3.04M	Perf YTD	-59.51%
Book/sh	-0.56	P/C	17.62	EPS next 5Y	-	ROE	-366.44%	52W High	5.50 -93.51%	Perf Year	-91.16%
Cash/sh	0.02	P/FCF	-	EPS past 3/5Y	20.66% -34.35%	ROIC	-	52W Low	0.15 135.96%	Perf 3Y	-96.66%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	24.67% 29.78%	Perf 5Y	-98.84%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	25.24%	Oper. Margin	-	ATR (14)	0.12	Perf 10Y	-98.21%
Dividend Ex-Date	-	Quick Ratio	0.03	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	46.45	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.03	EPS Q/Q	82.91%	SMA20	-2.36%	Beta	0.52	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-28.42%	Rel Volume	0.40	Prev Close	0.39
Employees	29	LT Debt/Eq	-	Earnings	-	SMA200	-74.99%	Avg Volume	18.41M	Price	0.36
IPO	Feb 02, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	- -	Trades		Volume	7,360,120	Change	-9.41%

Apr-07-26 10:30AM	BC-Most Active Stocks (Associated Press) +39.75%
09:05AM	Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion (PR Newswire)
Mar-26-26 08:50AM	Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications (PR Newswire) +22.94%
Mar-19-26 09:57AM	Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model (PR Newswire)
Feb-19-26 08:30AM	Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping (PR Newswire)
03:22PM	Loading…
Feb-17-26 03:22PM	Lunai Bioworks: Fiscal Q2 Earnings Snapshot (Associated Press Finance) -9.19%
Feb-13-26 08:31AM	Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC (PR Newswire) -10.21%
Feb-09-26 11:14AM	Lunai Bioworks, Inc. Issues Letter to Shareholders (PR Newswire) +24.67%
09:15AM	Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data (PR Newswire)
Jan-27-26 10:36AM	Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons (PR Newswire)
Jan-26-26 09:30AM	Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery (PR Newswire)
Dec-18-25 09:00AM	Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance (PR Newswire)
Dec-09-25 07:45AM	Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market (PR Newswire) -8.70%
Nov-25-25 07:45AM	Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models (PR Newswire) -14.96%
Nov-14-25 04:44PM	Lunai Bioworks: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
09:22AM	Loading…
Nov-05-25 09:22AM	Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy (PR Newswire) +40.29%
Oct-30-25 09:32AM	Lunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic Compounds (ACCESSWIRE)
Oct-16-25 09:45AM	Landmark Study Identifies Prognostic Biomarkers in Duchenne Muscular Dystrophy Using Large-Scale Serum Proteomics (ACCESSWIRE)
09:15AM	Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement (ACCESSWIRE)
Oct-06-25 09:15AM	Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative Pipeline (ACCESSWIRE)
Sep-25-25 08:30AM	Lunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma Partnerships (ACCESSWIRE) -18.54%
Sep-24-25 04:50PM	Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split (ACCESSWIRE) +5.63%
Sep-11-25 07:00AM	Lunai Bioworks subsidiary BioSymetrics and Brigham and Women's Hospital Awarded NIH STTR Grant to Develop AI-Powered Platform for Alcohol Use Disorder Therapeutics (ACCESSWIRE)
Sep-09-25 08:47AM	Lunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug Discovery (ACCESSWIRE) +18.18%
Sep-08-25 08:50AM	Lunai Bioworks Strengthens European Strategy Through Restructuring (ACCESSWIRE) -8.91%
Sep-04-25 10:05AM	Lunai Bioworks Inc. Retains American Defense International (ACCESSWIRE)
Aug-27-25 09:45AM	Renovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced Diagnostics (ACCESSWIRE) +12.03%
Aug-08-25 10:45AM	Renovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense Risks (ACCESSWIRE) +9.51%
Jul-29-25 03:01PM	AI Just Got a Green Light from the White House--Here's What That Means for Healthcare Stocks (PR Newswire) -8.02%
Jul-28-25 10:38AM	Renovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI Sector (ACCESSWIRE)
09:15AM	Loading…
Jul-17-25 09:15AM	Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor Efficacy (ACCESSWIRE) -7.05%
Jul-09-25 08:00AM	Renovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven Initiatives (ACCESSWIRE)
Jun-30-25 09:21AM	Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs (ACCESSWIRE)
Jun-10-25 11:13AM	Smart Healthcare Is Taking Over. Here's Where the Money's Headed (PR Newswire) +5.61%
Jun-03-25 09:15AM	Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform (GlobeNewswire)
May-23-25 09:17AM	AI Could Add $461 Billion to Global Healthcare--And These New Platforms Are Leading the Charge (PR Newswire)
May-22-25 09:41PM	Renovaro Inc. Accelerates 2025 Lawsuit to Force Predictive Oncology Merger (Insider Monkey) +15.28%
03:12PM	UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology (GlobeNewswire)
11:05AM	Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology (GlobeNewswire)
May-14-25 09:15AM	Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform (GlobeNewswire)
May-13-25 09:15AM	Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics (GlobeNewswire)
Apr-22-25 09:20AM	Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs (GlobeNewswire) -13.32%
Apr-09-25 09:25AM	Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine (GlobeNewswire)
Apr-05-25 12:10PM	China announces retaliatory tariffs, U.S. unemployment rises: Morning Buzz (TipRanks)
Apr-04-25 09:40AM	Renovaro Provides Update to Definitive Agreement with Predictive Oncology (GlobeNewswire) -16.49%
Mar-03-25 09:15AM	Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology (GlobeNewswire) -9.05%
09:00AM	Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences (GlobeNewswire)
Feb-26-25 01:25PM	Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine (GlobeNewswire) +53.95%
09:15AM	Renovaro Announces $15 million in Equity Committed (GlobeNewswire)
Feb-19-25 10:10AM	Investors Eye Biotech Sector as Cancer Therapy Market Surges (PR Newswire) +5.64%
Jan-07-25 09:15AM	Renovaro Issues Shareholder Letter and Provides Corporate Update (GlobeNewswire) -7.68%
09:15AM	Renovaro Appoints Nathen Fuentes as Chief Financial Officer (GlobeNewswire)
Jan-06-25 09:15AM	Renovaro to Acquire Predictive Oncology in All-Stock Transaction (GlobeNewswire) +7.99%
09:10AM	Predictive Oncology Announces Agreement to be Acquired by Renovaro (GlobeNewswire)
Dec-30-24 09:00AM	Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV (GlobeNewswire) -5.07%
Dec-23-24 09:00AM	RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program (GlobeNewswire) -31.71%
Dec-20-24 03:40PM	Renovaro Regains Compliance with NASDAQ Listing Requirement (GlobeNewswire) +6.15%
09:00AM	Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection (GlobeNewswire)
Nov-04-24 08:31AM	Renovaro Issues Shareholder Letter and Provides Corporate Update (GlobeNewswire) +15.44%
Oct-17-24 09:15AM	RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing (GlobeNewswire) -20.30%
Oct-16-24 09:28AM	Renovaro Announces Strategic Restructuring and Leadership Transition (GlobeNewswire) +32.01%
Sep-19-24 09:00AM	PersonalAIze and Cube Forge Groundbreaking Partnership to Accelerate AI-Driven Healthcare Platform and Point of Care Diagnostics (GlobeNewswire)
Sep-17-24 09:00AM	Independent Expert Assessment Validates RenovaroCube's Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection (GlobeNewswire) -5.16%
Sep-13-24 09:00AM	RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress (GlobeNewswire) +5.51%
Sep-11-24 09:15AM	RenovaroCube Announces Strategic Offering of Up to 20% Ownership (GlobeNewswire)
Jul-26-24 07:36AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
05:30AM	The Junk in Your Index Fund Is Costing You Big-Time (The Wall Street Journal)
Jun-14-24 09:06AM	Renovaro, Inc. Announces $10 million in Equity Committed (GlobeNewswire) +13.10%
May-24-24 09:20AM	Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy (GlobeNewswire) +7.58%
08:45AM	Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032 (GlobeNewswire)
May-16-24 08:53AM	RENB Stock Earnings: Renovaro Biosciences Reported Results for Q3 2024 (InvestorPlace)
Apr-30-24 11:00AM	Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics (GlobeNewswire)
Apr-24-24 09:00AM	RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership (GlobeNewswire)
Apr-18-24 08:45AM	Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care (GlobeNewswire)
Mar-04-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Chemours, Trupanion, and Renovaro and Encourages Investors to Contact the Firm (GlobeNewswire) +12.99% -7.28%
Feb-15-24 09:25AM	Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace (GlobeNewswire) -8.68%
Feb-14-24 10:01AM	Statement of Renovaro Inc (GlobeNewswire) +14.06%
Feb-13-24 09:46AM	Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace (GlobeNewswire) -42.86%
09:31AM	AI Pioneer GEDi Cube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine (GlobeNewswire)
Jan-25-24 12:45PM	Renovaro Biosciences Announces Results of Special Meeting of Shareholders (GlobeNewswire) +7.38%
Jan-18-24 09:30AM	Renovaro BioSciences Releases CEO Shareholder Message (NewMediaWire)
Jan-16-24 08:00AM	Message from Renovaro Bioscience, Inc.'s CEO, The Hon. Mark Dybul, MD (GlobeNewswire)
Nov-28-23 08:30AM	Renovaro BioSciences CEO Featured in Recent Proactive Interview (NewMediaWire) -5.83%
Nov-23-23 09:30AM	Renovaro BioSciences Poised to Spearhead Advancements in Battle Against Diseases (NewMediaWire)
Nov-22-23 10:44AM	Renovaro Biosciences CEO unveils potential breakthrough therapies and AI partnerships for 2024 (News Direct)
Nov-21-23 08:30AM	Renovaro BioSciences Eyes Opportunity in Precision Medicine Market (NewMediaWire)
Nov-14-23 09:00AM	Renovaro Biosciences CEO Provides Update on Combination with GEDiCube (NewMediaWire)
Nov-10-23 08:30AM	Renovaro BioSciences, GEDi Cube Combine to Transform Medicine Through AI, Biotherapeutics (NewMediaWire) +5.38%
Nov-07-23 08:30AM	Renovaro Biosciences Adds Three New Members to Board as Definitive Agreement with GEDiCube Announced (NewMediaWire)
Oct-24-23 09:00AM	Renovaro BioSciences CEO Provides Insights on Agreement to Combine with GEDi Cube (NewMediaWire) -7.61%
Oct-11-23 09:25AM	Avram Miller, Co-Founder of Intel Capital, Joins Renovaro Biosciences Board of Directors (GlobeNewswire) -5.89%
08:30AM	Renovaro BioSciences Announces Board Appointments of Two Finance Experts (NewMediaWire)
Oct-10-23 08:00AM	Renovaro Biosciences Appoints Two Finance Industry Experts to Board of Directors (GlobeNewswire) +19.08%
Oct-04-23 09:00AM	Renovaro BioSciences CEO Releases Shareholder Letter (NewMediaWire)
Oct-02-23 12:05PM	Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD (GlobeNewswire) +5.15%
09:25AM	AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine (GlobeNewswire)
08:30AM	Renovaro BioSciences Enters Definitive Agreement to Combine with Leading AI Tech GEDi Cube (NewMediaWire)
Sep-29-23 09:15AM	Renovaro Biosciences and AI Health Company GEDi Cube Sign Definitive Agreement to Combine (GlobeNewswire) +9.83%
09:15AM	GEDi Cube and Renovaro Biosciences Sign Definitive Agreement to Combine (Business Wire)
Sep-21-23 03:00PM	Renovaro BioSciences Targets Pancreatic Cancer Through Work With GEDI Cube AI Platform, NVIDIA Resources (NewMediaWire) +13.57%

Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LNAI

Lunai Bioworks Inc

Upgrade your Finviz experience